Stocktoria
ArriVent BioPharma, Inc. AVBP
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2024-01-26
Chart by TradingView
1/9
Piotroski F — financial health
10.94
Altman Z″ — distress risk · safe
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Financials | |||
| Operating income | -$177.5M | -$94.3M | -$74.6M |
| Net income | -$166.3M | -$80.5M | -$69.3M |
| Operating cash flow | -$160.6M | -$70.2M | -$55.8M |
| Total assets | $333.2M | $274.9M | $163.1M |
| Total liabilities | $25.9M | $17.3M | $11.8M |
| Shareholders' equity | $307.2M | $257.7M | -$153.2M |
| Ratios | |||
| Return on assets | -49.9% | -29.3% | -42.5% |
| Return on equity | -54.1% | -31.2% | 45.3% |
| Current ratio | 12.83 | 13.14 | 13.76 |
Notable holders (13F)
| Investor | Shares | Value |
|---|---|---|
| Point72 Asset Management, L.P. | 748,195 | $17.3M |
Why these scores methodology →
Piotroski F-score: 1/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 10.94 (safe)
- Working capital / assets 0.921
- Retained earnings / assets -1.215
- EBIT / assets -0.533
- Equity / liabilities 11.841
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001868279 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.